

JPET #246652

## Full title

Generation and Characterization of a Novel Small Biologic Alternative to PCSK9 Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein

## Authors

Yusuke Masuda, Shinji Yamaguchi, Chikako Suzuki, Takahide Aburatani, Yuki Nagano, Ryuki Miyauchi, Eiko Suzuki, Naotoshi Yamamura, Kentaro Nagatomo, Hidetoshi Ishihara, Kazuaki Okuno, Futoshi Nara, Gabriele Matschiner, Ryuji Hashimoto, Tohru Takahashi, and Tomohiro Nishizawa

*End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (Y.M., Y.N., T.N.)*

*Venture Science Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (S.Y.)*

*Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (C.S., T.A., R.M., R.H., T.T.)*

*Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (E.S., N.Y.)*

*Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (K.N., H.I., K.O.)*

*Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan (F.N.)*

*Pieris Pharmaceuticals GmbH, Freising, Germany (G.M.)*

JPET #246652

**Running title:** A novel small biologic alternative to PCSK9 antibodies

**Corresponding author:** Tomohiro Nishizawa

1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan

Tel.: +81-3-3492-3131, Fax: +81-3-5436-8587

E-mail: [nishizawa.tomohiro.yk@daiichisankyo.co.jp](mailto:nishizawa.tomohiro.yk@daiichisankyo.co.jp)

**The number of text pages:** 35

**The number of tables:** 1

**The number of figures:** 5

**The number of references:** 40

**The number of words in the Abstract:** 249

**The number of words in the Introduction:** 429

**The number of words in the Discussion:** 1497

**Abbreviations:**

ABD: albumin binding domain

AUC: area under the curve

$k_a$ : association rate constant

CETP: cholesteryl ester transfer protein

$K_D$ : dissociation constant

$k_d$ : dissociation rate constant

HDL-C: high-density-lipoprotein cholesterol

HSA: human serum albumin

LDL-C: low-density-lipoprotein cholesterol

LDL-R: low-density-lipoprotein receptor

ox-LDL: oxidized low-density lipoprotein

PCSK9: proprotein convertase subtilisin/kexin type 9

TC: total cholesterol

TG: triglyceride

$T_{1/2}$ : elimination half-life

JPET #246652

VLDL-C: very-low-density-lipoprotein cholesterol

Dil-LDL: 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate

Section assignment: Cardiovascular

JPET #246652

## Abstract

Since it was recently reported that an antibody for proprotein convertase subtilisin/kexin type 9 (PCSK9) reduced the risk of cardiovascular events in a clinical context, PCSK9 inhibition is thought to be an attractive therapy for dyslipidemia. In the present study, we created a novel small biologic alternative to PCSK9 antibodies called DS-9001a, comprising an albumin binding domain fused to an artificial lipocalin mutein (ABD-fused Anticalin protein), which can be produced by a microbial production system. DS-9001a strongly interfered with PCSK9 binding to low-density-lipoprotein receptor (LDL-R) and PCSK9-mediated degradation of LDL-R. In cynomolgus monkeys, single administration of DS-9001a reduced the serum LDL-C level by about 62.4% for more than 21 days. Moreover, DS-9001a reduced plasma non-high-density-lipoprotein cholesterol and oxidized LDL levels, and their further reductions were observed when atorvastatin and DS-9001a were administered in combination in human CETP/ApoB double transgenic mice. Additionally, their reductions upon the combination of atorvastatin and DS-9001a were more pronounced than those upon the combination of atorvastatin and anacetrapib. Besides its favorable pharmacological profile, DS-9001a has a lower molecular weight (about 22 kDa), yielding a high stoichiometric drug concentration that might result in a smaller administration volume than that in existing antibody therapy. Since bacterial production systems are viewed as more suited to mass production at low cost, DS-9001a may provide a new therapeutic option to treat a large number of patients with dyslipidemia. In addition, considering the growing demand for antibody-like drugs, ABD-fused Anticalin proteins could represent a promising new class of small biological molecules.

JPET #246652

## Introduction

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K secretory subtilisin-like subfamily of serine proteases, and is mainly expressed in the liver, kidney, and small intestine. PCSK9 binds to the low-density-lipoprotein receptor (LDL-R) and induces its degradation. Thus, PCSK9 inhibitors that block PCSK9-mediated LDL-R degradation reduce the plasma low-density-lipoprotein cholesterol (LDL-C) level (Dadu and Ballantyne, 2014). Strong evidence for the impact of PCSK9 on circulating LDL-C level and cardiovascular events has been provided by human genetic studies. Mutations in PCSK9 can lead to changes in its activity (gain or loss of function) that correlate with elevated or decreased plasma LDL-C levels and the risk of cardiovascular events (Abifadel et al., 2009). Moreover, recently, the treatment of statin-treated patients with evolocumab, a monoclonal anti-PCSK9 antibody, reduced cardiovascular events (Sabatine et al., 2017). Therefore, PCSK9 inhibition is a promising therapeutic strategy for dyslipidemia. However, antibodies on the market for treating dyslipidemia have a complex structure and a large size, leading to high production costs and a relatively high administration volume of the drug. Both of these issues can be solved with a PCSK9 inhibitor of a smaller molecular size.

Lipocalins are a family of proteins composed of a target binding loop region with high plasticity and a structurally rigid  $\beta$ -barrel scaffold. By introducing random mutations into their loop region and selecting products using their binding affinity to target proteins, it is possible to create artificial lipocalins that potently and specifically recognize the target protein, called Anticalin® proteins (Skerra, 2008). To date, we have reported tear lipocalin-derived Anticalin proteins that potently bind to VEGF-A (Gille et al., 2016) or to the extracellular domain of the c-met receptor (Olwill et al., 2013). Besides their vast repertoire of recognized ligands, Anticalin proteins can be easily produced by bacterial expression systems and exhibit robust biophysical properties. Although naked Anticalin proteins were reported to disappear rapidly from the blood, their plasma elimination half-life ( $T_{1/2}$ ) could be extended by connecting effector domains, such as via site-directed PEGylation (Gille et al., 2016). Considering these properties, Anticalin proteins with long  $T_{1/2}$  could be attractive pharmacological tools for PCSK9 inhibition.

In the present study, we generated an albumin binding domain-fused Anticalin protein (DS-9001a) that potently inhibits the binding of PCSK9 to LDL-R and has a long  $T_{1/2}$  by

JPET #246652

binding to circulating albumin. We investigated its pharmacokinetic and pharmacologic profiles in rodents and cynomolgus monkeys. We also compared the combined effects of DS-9001a and atorvastatin to the combination treatment of cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, and atorvastatin, or each monotherapy alone, on plasma lipid profiles.

JPET #246652

## Materials and Methods

### Animals

Male Sprague-Dawley (SD) rats and male C57BL/6J mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). Male B6.SJL-Tg(APOA-CETP)1Dsg Tg(APOB)1102Sgy N10 mice (human CETP/ApoB double Tg mice) were purchased at 7 weeks of age from CLEA Japan, Inc. (Tokyo, Japan). Animals were acclimatized for more than 3 days. Two to three rats or five mice were housed per cage and were given rodent chow (FR-2; Funabashi Farm Co., Ltd., Funabashi, Japan) and tap water ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. The experiments were performed in accordance with this committee's guidelines.

### Production of recombinant PCSK9 protein

Human PCSK9 containing a C-terminal FLAG tag (hPCSK9-Flag) was expressed in transfected HEK293F cells. Six hundred milliliters of transfected cells were cultivated in DMEM/ITS (insulin, transferrin, and selenium) containing 0.05% BSA for 6 days and the supernatant containing the produced hPCSK9-Flag was collected. hPCSK9-Flag was bound to FLAG M2 resin, washed with 50 column volumes of wash buffer (10 mM Tris-HCl, pH7.4, 150 mM NaCl, 2 mM CaCl<sub>2</sub>, 10% glycerol), and eluted with wash buffer containing 100 µg/mL 3× FLAG peptide. The eluted protein was further purified via gel filtration using a Superdex 200 16/60 column (GE Healthcare, Little Chalfont, UK).

For selection and screening of Anticalin proteins of interest, hPCSK9-Flag was biotinylated by incubation with a five times molar excess of EZ-Link NHS-Chromogenic Biotin reagent (Thermo Fisher Scientific, Waltham, MA) for 1 h at room temperature. Excess biotin was removed and the biotinylated protein was concentrated by ultrafiltration. The gain-of-function human PCSK9\_D374Y mutant (Cameron et al., 2006), cynomolgus PCSK9, and mouse PCSK9 were produced and characterized in the same way.

### Generation of a library with $2 \times 10^{10}$ independent Anticalin proteins and phagemid selection of Anticalin proteins against PCSK9

A random library of  $2 \times 10^{10}$  Anticalin proteins with high diversity was generated by random

JPET #246652

mutagenesis of mature human tear lipocalin (Gille et al., 2016). For selection of PCSK9-specific Anticalin proteins,  $2 \times 10^{12}$  phagemids from this library were incubated with 200 nM biotinylated human and/or cynomolgus PCSK9. Paramagnetic beads coated with neutravidin or streptavidin were used to capture PCSK9/phagemid complexes, which were subsequently isolated with a magnet. Unbound phagemids were removed by washing the beads eight times with 1 mL of PBS supplemented with 0.1% Tween-20 (v/v) (PBS-0.1%T). Bound phagemids were eluted by incubation first with triethylamine and then with 0.1 M glycine pH 2.2. Four consecutive rounds of selection were performed.

The mutagenized central cassette of the plasmid preparation obtained after phage display selection was isolated by digestion of the DNA with BstX1 and subsequent purification via agarose gel electrophoresis using standard methods. The DNA was inserted into the similarly cut vector pTlc10, which allows bacterial production of the Anticalin proteins under the control of a tetracycline promoter.  $\text{CaCl}_2$ -competent TG1-F' cells were transformed with the ligation mixture and plated on LB/Amp plates. Individual colonies were used to inoculate 2xYT/Amp medium and grown overnight (14–18 h) to stationary phase. Subsequently, 50  $\mu\text{L}$  of 2xYT/Amp was inoculated from the stationary-phase cultures and incubated for 3 h at 37°C and then shifted to 22°C until an  $\text{OD}_{595}$  of 0.6–0.8 was reached. Anticalin protein production was induced by the addition of 10  $\mu\text{L}$  of 2xYT/Amp supplemented with 1.2  $\mu\text{g/mL}$  anhydrotetracycline. Cultures were incubated at 22°C until the next day. After the addition of 40  $\mu\text{L}$  of 5% (w/v) BSA in PBS-0.1%T and incubation for 1 h at 25°C, cultures were ready for use in screening assays.

For the selection of Anticalin proteins, ELISA assay was performed. Specifically, human and cynomolgus PCSK9 (1  $\mu\text{g/mL}$  in PBS-0.1%T), which all carried a FLAG-tag, were captured on microplates using an anti-FLAG-tag antibody (Sigma-Aldrich, St. Louis, MO), which had been coated on the plates the day before at a final concentration of 5  $\mu\text{g/mL}$  in PBS. The anti-Flag-tag antibody alone served as a negative control. Subsequently, 20  $\mu\text{L}$  of BSA-blocked cultures were added and incubated for 1 h at 25°C. Bound Anticalin proteins were detected with a 1:10,000 dilution of anti-T7 antibody conjugated with horseradish peroxidase (HRP; Merck KgaA, Darmstadt, Germany) in PBS-0.1%T. For quantification, 20  $\mu\text{L}$  of QuantaBlu fluorogenic peroxidase substrate was added and measured at an excitation wavelength of 320 nm and an emission wavelength of 430 nm.



JPET #246652

## **Generation of a biased maturation library for optimization of PCSK9-specific Anticalin proteins**

For optimization of PCSK9-specific Anticalin proteins, additional libraries were generated based on initial hit clones (or parental Anticalin proteins). The libraries were generated in a manner that led to partial randomization of selected positions only by recursive PCR. Subsequently, the generated Anticalin proteins were cloned with high efficiency into a phagemid vector essentially as described previously (Kim et al., 2009). The library size ranged from  $7 \times 10^9$  to  $11 \times 10^9$  mutants. The libraries were employed in subsequent phage panning (Supplementary Methods).

## **Identification of PCSK9-specific Anticalin proteins by screening**

Selected Anticalin proteins from optimized Anticalin proteins were produced by *E. coli* and further selected in an ELISA assay as described above using the hPCSK9\_D374Y mutant to capture human and cynomolgus PCSK9. After the addition of 40  $\mu$ L of 5% (w/v) BSA in PBS-0.1%T and incubation for 1 h at 25°C, cultures were ready for use in screening assays.

For affinity ranking of Anticalin proteins, anti-Strep-tag antibody (IBA Lifesciences, Goettingen, Germany) in PBS was coated on microplates and 20  $\mu$ L of BSA-blocked cultures were added, which allowed specific capture of Anticalin proteins on the plate. Different concentrations (0.5–5 nM) of biotinylated PCSK9 proteins were added and specifically bound PCSK9 proteins were detected with extravidin-HRP (Sigma-Aldrich) after extensive washing. For quantification, 20  $\mu$ L of QuantaBlu was added and measured at an excitation wavelength of 320 nm and an emission wavelength of 430 nm.

The selection of competitive Anticalin proteins that can block the interaction of PCSK9 with LDL-R was performed by coating anti-FLAG-tag (5  $\mu$ g/mL in PBS) on microplates and subsequently capturing hPCSK9-D374Y mutant (1  $\mu$ g/mL in PBS-0.1%T). BSA-blocked cultures were adjusted to 30 nM recombinant human LDL receptor containing a C-terminal His tag and added for 72 h to plates with captured hPCSK9-D374Y mutant. This allowed equilibration of the system and the reliable selection of competitive Anticalin proteins. Bound receptor was detected with an HRP-conjugated anti-His-tag antibody (1  $\mu$ g/mL in PBS-0.1%T; Abcam, Cambridge, UK). For quantification, 20  $\mu$ L of QuantaBlu fluorogenic peroxidase

JPET #246652

substrate was added and measured at an excitation wavelength of 320 nm and an emission wavelength of 430 nm.

### **Expression and purification of PCSK9-specific Anticalin protein and DS-9001a**

From the biased maturation library screening, a PCSK9-specific Anticalin protein was obtained. This Anticalin protein was genetically fused with a deimmunized albumin binding domain (ABD) variant (Zurdo et al., 2015), and the fusion molecule was denoted DS-9001a (refer to SEQ ID NO: 83; Matschiner et al., 2014). DNA encoding DS-9001a or DS-9001a without ABD was inserted into a similarly cut vector, which allowed bacterial production under the control of a T5 promoter or a T7A3 promoter, and expressed in *E. coli*. The proteins were purified from cell lysates by a combination of column chromatography methods using an anion exchange column, phenyl Sepharose column, and gel filtration column. The purified proteins were finally solubilized in PBS. DS-9001a was also produced using a gram-positive *Corynebacterium glutamicum* expression system (CORYNEX®) of Ajinomoto Co., Inc. (Tokyo, Japan). The concentrations of undiluted purified DS-9001a used for the pharmacodynamic studies were 99.6–101.4 mg/mL (approximately 4.5–4.6 mM). Since these concentrations were too high to administer the intended amount of DS-9001a in rodents and monkeys accurately due to their small body weights, we diluted DS-9001a with control buffer and used this in the present study.

### **Evaluation of DS-9001a pharmacokinetic profile in rat**

DS-9001a or DS-9001a without ABD was intravenously injected into male SD rats (9 weeks old) at 10 or 7.6 mg/kg, respectively, which are equivalent to 0.45  $\mu$ mol/kg (n=3). Administration was conducted at 2.0 mL/kg. Blood was collected from the tail vein at 0.5, 1, 2, 4, 6, 8, 10, 24, 48, and 72 h after injection. Plasma was obtained by centrifugation (12,000 rpm, 5 min, 4°C). Detailed methods to evaluate the pharmacokinetic profile of DS-9001a and DS-9001a without ABD are described in Supplementary Method.

### **Measurement of binding affinity of DS-9001a and DS-9001a without ABD to human PCSK9 and human serum albumin (HSA)**

To measure the binding affinity of DS-9001a and DS-9001a without ABD to biotinylated

JPET #246652

PCSK9, a surface plasmon resonance-based assay was employed utilizing a Biacore T200 instrument (GE Healthcare) (Supplementary Method). The association rate constants ( $k_a$ ), dissociation rate constants ( $k_d$ ), and resulting dissociation constants ( $K_D$ ) were calculated using a 1:1 Langmuir binding model.

### **PCSK9 and LDL-R binding inhibition assay**

For this assay, biotin-labeled human PCSK9 (biotin-hPCSK9) was prepared as described below. Recombinant human PCSK9 protein (2.1 mg/mL; Thermo Fisher Scientific) was biotinylated by incubating with 10 mM EZ-Link Sulfo-NHS-LC-LC-Biotin (Thermo Fisher Scientific) for 85 min at room temperature. For purification, we used a Zeba Spin Desalting Column (Thermo Fisher Scientific) pre-equilibrated in elution buffer (20 mM HEPES, pH 7.4, 2 mM  $\text{CaCl}_2$ , 150 mM NaCl, 10% glycerol). The labeling reaction mixture described above was applied to the column followed by eluting with 100  $\mu\text{L}$  of elution buffer by centrifugation at  $1000 \times g$  for 2 min at  $4^\circ\text{C}$  to collect purified biotin-hPCSK9.

The 2  $\mu\text{g/mL}$  anti-LDL-R solution (R&D Systems, Minneapolis, MN) was added to a 96-well plate at 100  $\mu\text{L/well}$  and incubated overnight at  $4^\circ\text{C}$  to allow adhesion of the antibody to the plate. The next day, this plate was washed three times with DPBS and the wells were incubated with DPBS containing 1% skim milk (Becton, Dickinson and Company, Franklin Lakes, NJ) at room temperature for 1 h. After the plate had been washed three times with DPBS containing 0.05% Tween 20 (DPBS-0.05%T), the reaction mixtures that contained 3 mg/mL biotin-hPCSK9 and various concentrations of DS-9001a were added to the plate at 50  $\mu\text{L/well}$  ( $n=3$ ). Then, 0.4  $\mu\text{g/mL}$  recombinant human LDL-R (R&D Systems) was added to the plate at 50  $\mu\text{L/well}$ . As positive and negative controls, DS-9001a-deficient and LDL-R-deficient wells were prepared, respectively. After the plate had been incubated at room temperature for 2 h, the wells were washed three times with DPBS-0.05%T. Pierce High Sensitivity Streptavidin-HRP (Thermo Fisher Scientific) diluted 10,000-fold in DPBS-0.05%T containing 1% BSA was added to the plate at 100  $\mu\text{L/well}$  and then incubated at room temperature for 1 h.

The luminescent signal was measured using BM Chemiluminescence ELISA Substrate (POD) (Roche Diagnostics, Tokyo, Japan). After three washes with DPBS-0.05%T, POD working solution was then added to each well at 100  $\mu\text{L/well}$ . The plate was incubated at room

JPET #246652

temperature for 5 min in the dark and luminescent signals in each plate were measured using a multimode microplate reader (Molecular Devices, LLC, Sunnyvale, CA). The relative binding activity was calculated for each well using the following formula: Relative binding activity (%) =  $\frac{[(\text{luminescent signal in each well}) - (\text{luminescent signal in negative control wells})]}{[(\text{luminescent signal in positive control wells}) - (\text{luminescent signal in negative control wells})]} \times 100$ . In the binding inhibition assay in the presence of albumin, the reaction mixture contained 17 mg/mL human albumin (Sigma-Aldrich).

### **Cell-based inhibition of PCSK9-mediated LDL-R degradation assay**

HepG2 cells were seeded onto a 96-well plate and cultured with DMEM containing 10% FBS and 1% penicillin-streptomycin (PS; Thermo Fisher Scientific) in a CO<sub>2</sub> incubator (37°C with 5% CO<sub>2</sub>) overnight. The next day, the medium was changed to DMEM containing 5% Lipoprotein-Deficient Bovine Calf Serum (LPDS; Biomedical Technologies, Madrid, Spain) and 1% PS (LPDS medium) and the cells were cultured in a CO<sub>2</sub> incubator overnight. The next day after that, the medium was removed and LPDS medium containing various concentrations of DS-9001a was added to the cells (n=3). Then, LPDS medium containing 12 µg/mL human PCSK9 was added to the cells at 25 µL/well. As positive and negative controls, DS-9001a and PCSK9-deficient, or PCSK9-deficient wells were prepared, respectively. After incubation for 6 h in a CO<sub>2</sub> incubator, the medium was removed and the cells were fixed with Mildform 10N at room temperature for 20 min. The cells were then washed five times with PBS and incubated with PBS-0.1% NaN<sub>3</sub>-1% H<sub>2</sub>O<sub>2</sub> solution at room temperature for 20 min with gentle shaking. After the cells had been washed five times with PBS, they were incubated with PBS containing 3% BSA at room temperature for 90 min. Anti-LDL-R primary antibody (Progen Biotechnik, Heidelberg, Germany) diluted 600-fold in PBS containing 3% BSA was added to the cells and incubated at room temperature for 60 min. Then, the cells were washed five times with PBS and incubated with anti-Rabbit IgG, HRP-Linked F(ab')<sub>2</sub> Fragment (GE Healthcare) diluted 2000-fold in PBS containing 3% BSA at room temperature for 60 min. The luminescent signal was measured using POD (Roche Diagnostics). The cells were washed five times with PBS, after which POD working solution was added to each well at 75 µL/well. The plate was incubated at room temperature for 5 min in the dark and luminescent signals were measured using a multimode microplate reader

JPET #246652

(Molecular Devices, LLC) and calculated using the following formula: Relative activity (%) =  $\frac{[(\text{luminescent signal in each well}) - (\text{luminescent signal in negative control wells})]}{[(\text{luminescent signal in positive control wells}) - (\text{luminescent signal in negative control wells})]} \times 100$ . The amount of DS-9001a required for 50% inhibition of PCSK9 function ( $IC_{50}$ ) was determined by using a sigmoid Emax model and the analyses were performed using SAS System Release 9.2 (SAS Institute Inc., Cary, NC).

### **Inhibition of PCSK9-mediated LDL-R degradation in mice**

Vehicle, 0.3, or 3.0 mg/5.0 mL/kg DS-9001a was intravenously administered into mice. Thirty minutes after DS-9001a administration, 0.8 mg/kg mouse PCSK9 was administered intravenously. Liver was obtained 60 min after PCSK9 administration. Liver samples were lysed with RIPA buffer (Merck Millipore, Billerica, MA) with protease inhibitor (Nacalai Tesque, Kyoto, Japan), and centrifuged at 15,000 rpm and 4°C for 10 min. Supernatant was obtained and protein amounts were measured by a Pierce BCA Protein Assay Kit. An equal amount of protein was used for western blot analysis. LDL-R and  $\beta$ -actin were detected by anti-LDL-R antibody (R&D Systems) and anti- $\beta$ -actin antibody (Cell Signaling Technology, Danvers, MA), respectively.

### **Dil-labeled LDL clearance assay**

Approximately 24 h before the administration of lipoprotein labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (Dil-labeled LDL, Dil-LDL; Biomedical Technologies), 0.3 or 3.0 mg/5.0 mL/kg DS-9001a or vehicle was administered to mice intravenously. The next day, 200  $\mu$ g/mL Dil-LDL was administered and blood was collected 2 min, 0.5, 1, 2, 4, and 6 h later. Plasma was obtained by centrifugation and the plasma Dil-LDL level was determined based on fluorescence intensity (excitation wavelength: 520 nm, measurement wavelength: 590 nm). The area under the curve (AUC) of the plasma Dil-LDL level (from 2 min to 6 h after Dil-LDL injection) was calculated using the trapezoidal rule.

### **Atorvastatin combination study**

Human CETP/ApoB double Tg mice were treated with DS-9001a, anacetrapib, and

JPET #246652

atorvastatin, or a combination from among these drugs. The duration of the study was 8 days. Atorvastatin was administered by mixing with food (FR-2 powder chow diet containing 0.08% atorvastatin). Anacetrapib was administered orally once daily at 10 mg/kg from the initiation of the study (Day 1) to Day 7. DS-9001a was administered intravenously at 30 mg/kg on Days 1, 4, and 7. The dosing volume of DS-9001a was calculated to be 5.0 mL/kg based on the body weight. Blood was collected on Day 8 and plasma triglyceride (TG) and total cholesterol (TC) were measured using Triglyceride E-test Wako (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and Cholesterol E-test Wako (Wako Pure Chemical Industries, Ltd.), respectively. The ratio of high-density lipoprotein (HDL) and non-HDL was determined using an HPLC system (Tosoh Corporation, Tokyo, Japan), as described previously (Shimizu et al., 2002), and each cholesterol level was calculated by dividing plasma TC levels according to the ratio. Plasma oxidized LDL (ox-LDL) level was measured using Oxidized LDL ELISA kit (Mercodia AB, Uppsala, Sweden). Plasma PCSK9 level was measured using Mouse Proprotein Convertase 9/PCSK9 Quantikine ELISA Kit (R&D Systems).

### **Studies in monkey**

Male cynomolgus monkeys (2.8–6.0 kg) were maintained at Shin Nippon Biomedical Laboratories, Ltd., Drug Safety Research Laboratories (SNBL DSR, Kagoshima, Japan), under standard environmental conditions in individual cages. Solid food (HF Primate J 12G 5K9J; Purina Mills, LLC, Gray Summit, MO) was provided to each animal once daily and was available ad libitum from an automatic supply system. The study was approved by the IACUC (approval No. IACUC315-218) and was performed in accordance with the animal welfare bylaws of SNBL DSR, which is accredited by AAALAC International. Here, 0.3, 1, or 3 mg/kg DS-9001a or vehicle was intravenously administered to monkeys. The dosing volume was calculated to be 1 mL/kg based on the body weight. The endotoxin level in each dose was below 0.18 EU/kg and this value fell below the acceptable threshold for use in animals (Malyala and Singh, 2008). Serum LDL-C and HDL-C levels were measured by an automatic analyzer (JEOL Ltd., Tokyo, Japan).

JPET #246652

## Results

### Generation and characterization of PCSK9-specific ABD-fused Anticalin protein, DS-9001a

Anticalin proteins targeting PCSK9 were generated by using tear lipocalin-based phage display Anticalin libraries in selections against human PCSK9, the gain-of-function human PCSK9\_D374Y mutant, and cynomolgus PCSK9. The affinity of selected Anticalin proteins to PCSK9 was ranked, and through evaluation of the ability to block the interaction of PCSK9 and LDL-R, we identified a PCSK9-specific Anticalin protein. Since the Anticalin protein itself was expected to be rapidly eliminated from the body, ABD was fused to its C-terminus to prolong the  $T_{1/2}$  (Figure 1A).

Binding kinetics of DS-9001a and DS-9001a without ABD were measured using surface plasmon resonance (Biacore). The determined  $k_a$ ,  $k_d$ , and  $K_D$  are summarized in Table 1. Both DS-9001a and DS-9001a without ABD bind to human PCSK9 with  $K_D$  on the order of nanomoles, suggesting that 1) the Anticalin protein moiety of DS-9001a potentially interacts with PCSK9, and 2) fusion with ABD does not influence its affinity to PCSK9. The binding of DS-9001a to HSA was confirmed in this assay ( $K_D = 0.019$  nM).

To confirm the effect of ABD on extending plasma  $T_{1/2}$ , pharmacokinetic profiles after single dosing of DS-9001a and DS-9001a without ABD to rats were examined. Plasma concentration-time profiles after the intravenous administration of 10 mg/kg DS-9001a and 7.6 mg/kg DS-9001a without ABD, which corresponded to equal amounts of protein, are shown in Figure 1B. Plasma  $T_{1/2}$  of DS-9001a was  $24.3 \pm 3.1$  h, whereas that of DS-9001a without ABD was  $0.992 \pm 0.095$  h. This suggests that ABD dramatically extends the  $T_{1/2}$  of DS-9001a by tightly binding to circulating albumin in vivo.

### DS-9001a inhibits PCSK9-dependent LDL-R degradation

We examined the effects of DS-9001a on the binding between human PCSK9 and LDL-R in an in vitro cell-free assay. After the addition of a mixture of DS-9001a and human PCSK9 to an LDL-R-coated plate, the immobilized PCSK9 level was measured. As shown in Figure 2A, DS-9001a reduced the immobilized PCSK9 level in a dose-dependent manner, suggesting that DS-9001a inhibits the PCSK9 binding to LDL-R. Since DS-9001a binds to both PCSK9 and albumin, we next examined whether this inhibitory effect of DS-9001a was interfered with

JPET #246652

by the presence of albumin. As shown in Figure 2B, we confirmed that the inhibitory activity of DS-9001a was maintained even in the presence of albumin. This inhibitory effect was also observed in mouse, rat, and monkey PCSK9 (Supplementary Figure 1). To verify that DS-9001a disturbs the PCSK9-mediated LDL-R degradation as previously demonstrated by anti-PCSK9 antibody (Liang et al., 2012), HepG2 cells were incubated with DS-9001a and PCSK9, and the cell surface LDL-R level was determined using anti-LDL-R antibody. The treatment of PCSK9 reduced cell surface LDL-R expression and DS-9001a treatment reversed it, with an  $IC_{50}$  value of 6.7 nM (Figure 2C), indicating that DS-9001a potently inhibits PCSK9-mediated LDL-R degradation. To evaluate further the PCSK9 inhibitory effect of DS-9001a in vivo, DS-9001a and PCSK9 were injected into mice and the hepatic LDL-R level was determined. As shown in Figure 2D, the administration of DS-9001a prior to PCSK9 injection rescued PCSK9-mediated LDL-R reduction. All of these findings together suggest that DS-9001a is a potent and functional PCSK9 inhibitor both in vitro and in vivo.

### **DS-9001a enhances LDL-C clearance in mice**

Next, to determine the effect of DS-9001a on the metabolism of LDL-C in vivo, we injected Dil-LDL into C57BL/6J mice approximately 24 h after the administration of DS-9001a and determined the transition of plasma Dil-LDL concentrations (Figure 3A). A single intravenous administration of DS-9001a at dosages of 0.3 and 3.0 mg/kg prior to Dil-LDL injection showed statistically significant lowering of the AUC of the plasma Dil-LDL level (from 2 min to 6 h after Dil-LDL injection) in a dose-dependent manner (Figure 3B). This suggests that DS-9001a treatment enhances LDL-C clearance in vivo.

### **DS-9001a reduces LDL-C in cynomolgus monkeys**

To examine further the pharmacological profile of DS-9001a in lipid metabolism, DS-9001a was administered intravenously at dose levels of 0 (control), 0.3, 1, and 3 mg/kg to healthy cynomolgus monkeys. Single DS-9001a administration significantly decreased serum LDL-C from 24 h after dosing, which then returned to the same level as the pre-dosing value within 240, 504, and 672 h from dosing at 0.3, 1, and 3 mg/kg, respectively (Figure 4A). The duration of the LDL-C suppressive effect was prolonged in a dose-dependent manner. The PCSK9 level was reported to reach the maximum value at 10 days after single intravenous injection of



JPET #246652

10 mg/kg 1B20, an anti-PCSK9 antibody, or 5 mg/kg BMS-962476, a small biologic PCSK9 inhibitor, in monkey (Zhang et al., 2012; Mitchell et al., 2014). In the present study, the serum DS-9001a level at 10 days after the administration of 3 mg/kg DS-9001a was approximately 1  $\mu$ M, which was considerably higher than the reported baseline (5 nM) and maximum (15–27 nM) monkey PCSK9 levels. The terminal half-life of DS-9001a in the 3 mg/kg injection group was  $128 \pm 90$  h (Supplementary Figure 2). There were no differences in serum HDL-C between the DS-9001a and control groups (Figure 4B). Subcutaneous injection is performed for the current anti-PCSK9 antibody therapies. Plasma  $T_{1/2}$  value was  $116 \pm 49$  h when 3 mg/kg DS-9001a was administered to cynomolgus monkey by subcutaneous injection, which was a similar value to that in intravenous injection. The absolute bioavailability was approximately 90% (data not shown). These results suggest that DS-9001a has a potent ability to elicit a sustained LDL-C reduction via beneficial binding to albumin in vivo.

#### **A synergistic effect of DS-9001a with atorvastatin on the reduction of plasma non-HDL-C and ox-LDL levels**

Since statin treatment is reported to increase both LDL-R and PCSK9 levels (Dubuc et al., 2004), it has often been proposed in the literature that there is a synergistic effect between statin and PCSK9 inhibitor (Rashid et al., 2005; Chan et al., 2009; Liang et al., 2012). In line with this theory, DS-9001a administration to mice showed an increase in hepatic LDL-R, which was further increased in combination with atorvastatin (Figure 5A).

Since CETP inhibitor increases HDL-C and reduces LDL-C levels, this inhibitor is thought to be another potential drug candidate for dyslipidemia (Bochem et al., 2013). Indeed, many studies reported that PCSK9 and CETP inhibitors were efficacies for the treatment of dyslipidemia. Nevertheless, there are no reports comparing the effects of these two classes of compounds and each combination with standard therapy, namely, statin treatment, on plasma lipids. Therefore, we examined the effects of a CETP inhibitor, anacetrapib, and DS-9001a on circulating lipid profiles, as well as those of each of them in combination with atorvastatin. Human CETP/ApoB double Tg mice were treated with DS-9001a, anacetrapib, and atorvastatin, or a combination from among these drugs, for a week, after which plasma lipid profiles were analyzed. As expected, atorvastatin monotherapy increased the plasma PCSK9 level (Figure 5B). The increase in PCSK9 level upon the coadministration of atorvastatin and

JPET #246652

anacetrapib was similar to that in atorvastatin monotherapy. The plasma PCSK9 level in DS-9001a-treated mice was considerably increased compared with that in control mice, and a further increase was shown in mice with the coadministration of atorvastatin. The increase in plasma PCSK9 was also observed for other PCSK9 inhibitors, such as anti-PCSK9 antibody (Zhang et al., 2012) or BMS-962476 (Mitchell et al., 2014). This phenomenon was interpreted to be due to the delayed clearance of PCSK9 through LDL-R endocytosis. Previously, anacetrapib was reported to reduce plasma PCSK9 level (Roddy et al., 2014; Millar et al., 2015; van der Tuin et al., 2015), but we did not observe a difference of this kind in anacetrapib treatment compared with vehicle treatment. The reason for this difference is unclear. Van der Tuin et al. observed PCSK9 reduction in mice and they administered 30 mg/kg anacetrapib for three to four weeks, but we applied it at 10 mg/kg for a week. Thus, the lower dose of anacetrapib or the relatively short period of administration in our study may have contributed to this difference.

Statin treatment is reported to inhibit very-low-density-lipoprotein cholesterol (VLDL-C) production and thereby reduce plasma TG level (Ginsberg, 1998). Consistent with this, we identified a reduction in plasma TG in atorvastatin-treated mice. This TG reduction was not enhanced in combination treatment with either anacetrapib or DS-9001a (Figure 5C). Atorvastatin and DS-9001a monotherapies decreased the plasma TC level significantly, and notably, coadministration of atorvastatin and DS-9001a showed a further reduction compared with their respective monotherapies (Figure 5D).

As shown in Figure 5E, atorvastatin and DS-9001a monotherapies revealed significant reductions of plasma non-HDL-C level compared with that upon vehicle administration. Anacetrapib monotherapy also exhibited a trend of non-HDL-C reduction, although this was not statistically significant. The combination treatments of DS-9001a or anacetrapib with atorvastatin further reduced the non-HDL-C level compared with their respective monotherapies. Moreover, the extent of reduction upon the combination of DS-9001a and atorvastatin was greater than that upon the combination of anacetrapib and atorvastatin, possibly due to the synergistic effect between statin and PCSK9 inhibitor, as described above. Regarding HDL-C (Figure 5F), anacetrapib monotherapy increased the plasma HDL-C level significantly, as expected, whereas the treatment combining anacetrapib with atorvastatin did not show an additive increase. Atorvastatin and DS-9001a monotherapies did not change the

JPET #246652

HDL-C level significantly, while a significant reduction compared with the vehicle treatment was observed when they were administered in combination.

Ox-LDL has been proposed as a more atherogenic lipoprotein particle than LDL-C (Steinberg, 1997), so we next examined whether monotherapies or the combination of these agents affect the plasma ox-LDL level. DS-9001a monotherapy reduced the plasma ox-LDL level compared with that upon vehicle treatment, and ox-LDL was further reduced when atorvastatin and DS-9001a were administered in combination. In addition to non-HDL-C reduction, these results suggest that DS-9001a and atorvastatin have a synergistic effect on the reduction of plasma ox-LDL level.

JPET #246652

## Discussion

Anti-PCSK9 antibody therapy has been shown to induce a major reduction of plasma LDL-C level, and has also recently been associated with a reduction of cardiovascular events in patients with atherosclerotic cardiovascular disease who were receiving statin therapy (Sabatine et al., 2017). Therefore, PCSK9 inhibition is thought to be an attractive therapy for hypercholesterolemia.

In the present study, we generated a novel small biologic alternative to PCSK9 antibodies, DS-9001a, which can be produced by using a bacterial expression system. DS-9001a inhibits the binding of PCSK9 to LDL-R in vitro; thus, DS-9001a attenuated PCSK9-mediated LDL-R degradation both in vitro and in vivo. We also observed that DS-9001a treatment enhanced LDL-C clearance and non-HDL-C reduction in mice. In addition, the sustained LDL-C lowering effect of DS-9001a was observed in cynomolgus monkeys. We also found an increase in hepatic LDL-R upon DS-9001a injection, and observed a further LDL-R increase upon combination treatment of atorvastatin and DS-9001a. In line with this, this combination exhibited a greater reduction in non-HDL-C level than the corresponding monotherapies. These findings are generally consistent with the properties of anti-PCSK9 antibodies. Therefore, we successfully produced a small biologic molecule that can be produced by a bacterial expression system, showing pharmacological and pharmacokinetic profiles comparable with those of therapeutic antibody.

In our study, the extent of non-HDL-C reduction for the combination of atorvastatin and DS-9001a was more pronounced than the combination of atorvastatin and anacetrapib. In clinical trials, anti-PCSK9 antibodies typically reduce the LDL-C level by approximately 60%, and anacetrapib reduces LDL-C by about 45% (Barter et al., 2015). Thus, the pharmacological effect shown in our data was almost consistent with the clinical data. Here, anacetrapib treatment increased plasma HDL-C, whereas a reduction in plasma HDL-C was observed upon combined treatment with DS-9001a and atorvastatin. The plasma HDL-C reduction shown in PCSK9 inhibition, however, is thought to be a specific phenomenon in rodents (Rashid et al., 2005; Mitchell et al., 2014). To investigate the precise impact of the lipid-modulating effects of these compounds to prevent cardiovascular events, further clinical study is required.

Increasing evidence has shown that ox-LDL is more atherogenic than native LDL-C

JPET #246652

(Steinberg, 1997), and plasma ox-LDL level was shown to be significantly elevated in patients with coronary artery disease (Holvoet et al., 1998). In this study, DS-9001a-treated mice exhibited plasma ox-LDL reduction, whereas anacetrapib did not reduce ox-LDL. It is known that ox-LDL exists in various forms, characterized by different degrees of oxidation and different regions where oxidation has occurred (Parthasarathy et al., 2010). Here, we measured plasma ox-LDL by using the antibody 4E6, which was previously used to show the correlation between plasma ox-LDL and coronary artery disease (Holvoet et al., 1998). Therefore, besides the LDL-C lowering effect, the ox-LDL reducing effect is a possible contributor to the reduction of cardiovascular events by PCSK9 inhibition therapy. Among the monotherapies, only DS-9001a monotherapy reduced the plasma ox-LDL level compared with that upon vehicle administration, despite the similar reductions of non-HDL-C between atorvastatin and DS-9001a treatments. It is thought that statin treatment increases hepatic LDL-R level, which is the main mechanism behind its LDL-C lowering effect in humans (Lennernäs and Fager, 1997). In contrast, in mice, statin is reported not to increase hepatic LDL-R level and to reduce non-HDL-C mainly through inhibiting VLDL-C production (Rashid et al., 2005). Here, we also did not observe hepatic LDL-R elevation in statin-treated mice. In addition, ox-LDL was further reduced when atorvastatin and DS-9001a were administered in combination, the same condition in which a further increase in hepatic LDL-R levels was observed. These results suggest that ox-LDL reduction is correlated with the hepatic LDL-R level.

Given the high cost of anti-PCSK9 antibody therapy, which is about 100 times more expensive than statin treatment, discussions among healthcare providers, guideline committees, and payers are required to identify whom to treat with this therapy (Preiss and Baigent, 2017). The large patient population together with the chronic state of the disease requiring lifelong treatment indicates the benefits that less expensive PCSK9 inhibitors would have for both patients and the finances of healthcare systems. In this regard, microbial expression, by which DS-9001a can be produced, is considered to be suitable for large-scale production at lower costs. The small size of DS-9001a (a molecular weight of about 22 kDa) enables higher stoichiometric drug concentrations (4.5 mM) to be achieved compared with those for anti-PCSK9 antibodies [e.g., 140 mg/mL evolocumab (about 1.0 mM) and 150 mg/mL alirocumab (about 1.0 mM)]. Considering that two PCSK9 molecules can be captured

JPET #246652

by one anti-PCSK9 antibody, whereas DS-9001a reveals a 1:1 interaction, the higher achievable drug concentration of DS-9001a could lead to a smaller administration volume compared with those for antibody drugs. Moreover, the longer terminal half-life of DS-9001a ( $128 \pm 90$  h) than that of AMG145 ( $61 \pm 9$  h) (Chan et al., 2009) in cynomolgus monkey correlates nicely with an extended pharmacological effect, as observed upon single intravenous administration of 3 mg/kg of the drug. This led to an LDL-C lowering effect for more than 21 days, but only for 14 days for the anti-PCSK9 antibody AMG145. Although we did not directly compare the durations of LDL-C reduction of DS-9001a and other anti-PCSK9 antibodies, the LDL-C lowering effect of DS-9001a seems to last longer than that of other anti-PCSK9 antibodies (Liang et al., 2012; Zhang et al., 2012). In clinical studies, evolocumab, AMG145, is dosed at 420 mg/body every month or 140 mg/body every two weeks (Sabatine et al., 2017), and alirocumab is injected at 75 or 150 mg/body every two weeks (Schwartz et al., 2014). The dosing regimen of evolocumab (420 mg/body per month) requires three consecutive injections with a syringe containing 1 mL of drug each ([https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/125522s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf)). It is reported that the dosing volume of subcutaneously administered drugs is closely related to their VAS score (Jørgensen et al., 1996), an indicator of pain upon injection. Therefore, the smaller administration volume for DS-9001a is a clear advantage as it avoids the burden of multiple high-volume injections. Additionally, the longer duration of LDL-C lowering of DS-9001a may enable extension of the dose interval, which in turn reduces the frequency of injections and hospital visits. Since it was reported that drugs with a low price, low dosing frequency, and small dosing volume show high medication adherence in injection therapy (Tkacz et al., 2014), the characteristics of DS-9001a would be preferred as a PCSK9 inhibitor. The safety profile of Anticalin therapeutics is supported by positive phase I study results for Angiocal, another Anticalin protein targeting VEGF-A (Mross et al., 2013). For DS-9001a, we have not observed any treatment-related adverse effects upon the single dosing of cynomolgus monkeys. Generally, this type of new biologic approach could be susceptible to the formation of anti-drug antibodies. Although we used human tear lipocalin mutein to generate DS-9001a to reduce the risk of anti-drug antibodies forming, we need to be vigilant on this issue in clinical study. Taking these findings together, although the safety profile and efficacy of DS-9001a in humans require further investigation, DS-9001a could become an

JPET #246652

attractive PCSK9 inhibitor.

Since Anticalin proteins are rapidly eliminated from the body due to their small size (approximately 17 kDa), an ABD was fused to Anticalin protein's C-terminus to prolong its plasma  $T_{1/2}$  by binding to HSA. Several other technologies that can extend the  $T_{1/2}$  of drugs have been reported, such as site-directed PEGylation (Roberts et al., 2002), direct fusion of albumin (70 kDa) to drugs (Osborn et al., 2002), or fusion to the Fc portion of an antibody (Wu and Sun, 2014). The smaller size and structural simplicity of an Anticalin protein-ABD fusion facilitates the manufacturing process using a microbial expression system and also confers a half-life that is similar to those of antibodies. To the best of our knowledge, this is the first time that an ABD fusion protein has been shown to have a prolonged  $T_{1/2}$  and sustained efficacy in non-human primates. Given the growing demand for antibody-like drugs, ABD-fused Anticalin proteins could represent a promising new class of small biological molecules for wider therapeutic targets.

In conclusion, we created a novel small biologic alternative to PCSK9 antibodies, DS-9001a. DS-9001a potently binds to PCSK9, thereby preventing PCSK9-mediated LDL-R degradation. A reduction of LDL-C by approximately 62.4% was observed following single DS-9001a injection in cynomolgus monkeys, and this effect was sustained for more than three weeks. Besides its robust pharmacology, DS-9001a can be manufactured by utilizing a microbial expression system, possibly reducing production costs. Furthermore, the high solubility and smaller size of the ABD-fused Anticalin protein enable the administration of higher drug concentrations at lower volumes, which can improve patient compliance by reducing the burden of multiple painful injections. Therefore, DS-9001a may have potential as a new therapeutic option to treat a large number of patients with dyslipidemia. In addition, since the ABD-fused Anticalin protein reveals similar characteristics to antibodies in terms of target specificity and long pharmacokinetics, this novel technology could be applicable for a wider range of therapeutic areas in which antibodies are prescribed.

JPET #246652

## Acknowledgments

We are grateful to Ms. Haruka Endo, Dr. Takanori Aoki, and Mr. Makoto Yoshida for their experimental assistance. We would also like to thank Mr. Manabu Kato, Dr. Yoichiro Shiba, Dr. Koichi Nonaka, and Dr. Jun Hasegawa for their helpful suggestions.

## Authorship contributions

*Participated in research design:* Masuda, Yamaguchi, Nara, Hashimoto, and Nishizawa.

*Conducted experiments:* Masuda, Yamaguchi, Nagano, Miyauchi, E. Suzuki, Yamamura, and Nishizawa.

*Contributed new reagents and analytic tools:* C. Suzuki, Aburatani, Nagatomo, Ishihara, Okuno, Hashimoto, and Takahashi.

*Performed data analysis:* Masuda, Nagano, Miyauchi, E. Suzuki, Yamamura, and Nishizawa.

*Wrote or contributed to the writing of the manuscript:* Masuda, Yamaguchi, Hashimoto, Matschiner, and Nishizawa.



JPET #246652

## References

Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, and Boileau C (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. *Hum Mutat* **30**: 520–529.

Barter PJ, Tabet F, and Rye KA (2015) Reduction in PCSK9 levels induced by anacetrapib: an off-target effect? *J Lipid Res* **56**: 2045–2047.

Bochem AE, Kuivenhoven JA, and Stroes ES (2013) The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. *Curr Pharm Des* **19**: 3143–3149.

Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, and Leren TP (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. *Hum Mol Genet* **15**: 1551–1558.

Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, Daris M, Sheng J, Wang Y, Shen WD, Yeh WC, Emery M, Walker NP, Shan B, Schwarz M, and Jackson SM (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. *Proc Natl Acad Sci USA* **106**: 9820–9825.

Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, and Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* **376**: 1670–1681.

Dadu RT and Ballantyne CM (2014) Lipid lowering with PCSK9 inhibitors. *Nat Rev Cardiol* **11**: 563–575.

JPET #246652

Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, and Prat A (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol* **24**: 1454–1459.

Ferri N, Corsini A, Macchi C, Magni P, and Ruscica M (2016) Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. *Transl Res* **173**: 19–29.

Ginsberg HN (1998) Effects of statins on triglyceride metabolism. *Am J Cardiol* **81**: 32B–35B.

Gille H, Hülsmeier M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, and Skerra A (2016) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. *Angiogenesis* **19**: 79–94.

Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, and Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. *Circulation* **98**: 1487–1494.

Kim HJ, Eichinger A, and Skerra A (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. *J Am Chem Soc* **131**: 3565–3576.

Kingwell BA, Chapman MJ, Kontush A, and Miller NE (2014) HDL-targeted therapies: progress, failures and future. *Nat Rev Drug Discov* **13**: 445–464.

Levitan I, Volkov S, and Subbaiah PV (2010) Oxidized LDL: diversity, patterns of recognition, and pathophysiology. *Antioxid Redox Signal* **13**: 39–75.

Jørgensen JT, Rømsing J, Rasmussen M, Møller-Sonnergaard J, Vang L, and Musaeus L

JPET #246652

(1996) Pain assessment of subcutaneous injections. *Ann Pharmacother* **30**: 729–732.

Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, Wu S, Chin SM, Lee NA, Rossi A, Lin JC, Rajpal A, Pons J, and Shelton DL (2012) Proprotein convertase subtilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. *J Pharmacol Exp Ther* **340**: 228–236.

Lennernas H and Fager G (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. *Clin Pharmacokinet* **32**: 403–425.

Malyala P and Singh M (2008) Endotoxin limits in formulations for preclinical research. *J Pharm Sci* **97**: 2041–2044.

Matschiner G, Rothe C, Hohlbaum A, Bel Aiba RS, Hinner M, Allersdorfer A, Lunde B, Wiedenmann A, Yamaguchi S, Aburatani T, Hashimoto R, Takahashi T, Nagasaki C, Nara F, and Nishizawa T (2014) NOVEL BINDING PROTEINS FOR PCSK9. WO 2014/140210 A1.

Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, and Pollan L (2015) Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. *J Clin Invest* **125**: 2510–2522.

Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D, Low S, Russo K, DiBella R, Denhez F, Gao M, Myers J, Duke G, Witmer M, Miao B, Ho SP, Khan J, and Parker RA (2014) Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. *J Pharmacol Exp Ther* **350**: 412–424.

Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, and Scheulen ME (2013) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. *PLoS One* **8**: e83232.

JPET #246652

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeier M, Trentmann S, Jensen K, Hohlbaum AM, and Audoly L (2013) A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. *Mol Cancer Ther* **12**: 2459–2471.

Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, and Sung C (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. *J Pharmacol Exp Ther* **303**: 540–548.

Parthasarathy S, Raghavamenon A, Garelnabi MO, and Santanam N. (2010) Oxidized low-density lipoprotein. *Methods Mol Biol* **610**: 403–417.

Preiss D and Baigent C (2017) Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? *Nat Rev Nephrol* **13**: 450–451.

Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, and Horton JD (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. *Proc Natl Acad Sci USA* **102**: 5374–5379.

Roberts MJ, Bentley MD, and Harris JM (2002) Chemistry for peptide and protein PEGylation. *Adv Drug Deliv Rev* **54**: 459–476.

Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, Donnelly M, Gai C, Gewain A, Lederman H, Jensen KK, Ai X, Vachal P, Akinsanya KO, Cleary MA, Previs SF, Dansky HM, and Johns DG (2014) Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. *Eur J Pharmacol* **740**: 410–416.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and

JPET #246652

Investigators (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med* **376**: 1713–1722.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, and Steg PG (2014) Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. *Am Heart J* **168**: 682–689.

Shimizu-gawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, and Furukawa H (2002) ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. *J Biol Chem* **277**: 33742–33748.

Skerra A (2008) Alternative binding proteins: anticalins harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. *FEBS J* **275**: 2677–2683.

Steinberg D (1997) Low density lipoprotein oxidation and its pathobiological significance. *J Biol Chem* **272**: 20963–20966.

Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. *Clin Ther* **36**: 737–747.

van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y (2015) Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. *J Lipid Res* **56**: 2085–2093.

Wu B and Sun YN (2014) Pharmacokinetics of peptide-Fc fusion proteins. *J Pharm Sci* **103**:

JPET #246652

53–64.

Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, and Sitlani A (2012) An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. *Int J Biol Sci* **8**: 310–327.

Zurdo J, Arnell A, Obrezanova O, Smith N, Gómez de la Cuesta R, Gallagher TR, Michael R, Stallwood Y, Ekblad C, Abrahmsén L, and Höidén-Guthenberg I (2015) Early implementation of QbD in biopharmaceutical development: a practical example. *Biomed Res Int* **2015**: 605427.

JPET #246652

## Footnotes

Y.M. and S.Y. contributed equally to this work.

## Financial Disclosure

This work was supported by Daiichi Sankyo Co., Ltd.

## Reprint requests to

Tomohiro Nishizawa

End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd.

1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan

E-mail: nishizawa.tomohiro.yk@daiichisankyo.co.jp

JPET #246652

## Figure Legends

### Figure 1

#### Pharmacokinetics of DS-9001a and DS-9001a ABD.

(A) Schematic illustration of DS-9001a structure. The Anticalin protein was genetically fused with albumin binding domain (ABD) through a Gly-Gly-Gly linker to extend the plasma elimination half-life ( $T_{1/2}$ ). The approximate molecular weight (MW) is indicated. (B) DS-9001a or DS-9001a without ABD was intravenously injected into male Sprague-Dawley (SD) rats (9 weeks old) at 10 or 7.6 mg/kg, respectively, which are equivalent to 0.45  $\mu$ mol/kg. Blood was collected from the tail vein at 0.5, 1, 2, 4, 6, 8, 10, 24, 48, and 72 h after injection. Plasma DS-9001a and DS-9001a without ABD were measured. The results are presented as mean + SE (n=3).

### Figure 2

#### DS-9001a prevents PCSK9-dependent LDL-R degradation.

Biotin-labeled human PCSK9 and DS-9001a were added to an anti-LDL-R antibody-coated plate in the (A) absence or (B) presence of human serum albumin (HSA). Then, human LDL-R was added to the plate and the plate was incubated for 2 h. The level of PCSK9 captured by LDL-R was detected with streptavidin-HRP. As positive and negative controls, DS-9001a-deficient and LDL-R-deficient wells were prepared, respectively. The relative binding activity (%) was calculated using the following equation: Relative binding activity =  $\frac{[(\text{luminescent signal in each well}) - (\text{luminescent signal in negative control wells})]}{[(\text{luminescent signal in positive control wells}) - (\text{luminescent signal in negative control wells})]} \times 100$ . The results are presented as mean  $\pm$  SE (n=3). (C) After HepG2 cells had been treated with DS-9001a, human PCSK9 protein was added to the cells and incubated for 6 h. The level of cell surface LDL-R was detected with anti-LDL-R antibody. As positive and negative controls, DS-9001a and PCSK9-deficient, or PCSK9-deficient wells were prepared, respectively. The relative activity (%) was calculated using the following equation: Relative binding activity =  $\frac{[(\text{luminescent signal in each well}) - (\text{luminescent signal in negative control wells})]}{[(\text{luminescent signal in positive control wells}) - (\text{luminescent signal in negative control wells})]} \times 100$ . The results are presented as mean  $\pm$  SE (n=3). (D) Vehicle, 0.3, or 3 mg/kg DS-9001a was intravenously administered into C57BL/6J mice. Thirty minutes after



JPET #246652

DS-9001a administration, 0.8 mg/kg mouse PCSK9 was administered intravenously. Liver was obtained 60 min after PCSK9 administration and lysates of liver samples were separated by SDS-PAGE and probed with anti-LDL-R antibody (n=3).

### Figure 3

#### **DS-9001a administration enhances LDL-C clearance in C57BL/6J mice.**

(A) Vehicle, 0.3, or 3 mg/kg DS-9001a was intravenously administered into C57BL/6J mice. Approximately 24 h after administration, low-density lipoprotein labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (DiI-LDL) was injected into all mice. The plasma concentrations of DiI-LDL 2 min, 0.5, 1, 2, 4, and 6 h after DiI-LDL administration were measured. The results are presented as mean  $\pm$  SE (n=6). (B) The area under the curve (AUC) of the plasma DiI-LDL level after DiI-LDL administration (2 min to 6 h). The results are presented as mean  $\pm$  SE (n=6). \* $P$  < 0.05, \*\*\* $P$  < 0.001, statistically significant compared with the control group, # $P$  < 0.05, statistically significant compared with the group with DS-9001a at 0.3 mg/kg (Tukey's test).

### Figure 4

#### **Single DS-9001a administration reduces LDL-C in cynomolgus monkeys.**

Vehicle, 0.3, 1.0, or 3.0 mg/kg DS-9001a was intravenously administered into cynomolgus monkeys, and the blood was collected at specific time points. Serum LDL-C and HDL-C levels were measured. The data were calculated as the percent of change from baseline, and are presented as mean  $\pm$  SE (n=6). \* $P$  < 0.05, \*\* $P$  < 0.01, statistically significant compared with the control group (Dunnett's test).

### Figure 5

#### **Combined effects of DS-9001a with atorvastatin on plasma lipids in human CETP/ApoB double Tg mice.**

(A) C57BL/6J mice were treated with atorvastatin by mixing it with food (FR-2 powder chow diet containing 0.08% atorvastatin) for 5 days. Vehicle or 30 mg/kg DS-9001a was intravenously injected on Day 3, liver was obtained about 48 h after PCSK9 administration, and lysates of liver samples were separated by SDS-PAGE and probed with anti-LDL-R

JPET #246652

antibody (n=3). (B–G) Male B6.SJL-Tg(APOA-CETP)1Dsg Tg(APOB)1102Sgy N10 mice (human CETP/ApoB double Tg mice) were treated with DS-9001a, anacetrapib, and atorvastatin, or a combination from among these drugs, for a week. Atorvastatin was administered by mixing with food (FR-2 powder chow diet containing 0.08% atorvastatin). Anacetrapib was administered orally once daily at 10 mg/kg from the initiation of the study (Day 1) to Day 7. DS-9001a was administered intravenously at 30 mg/kg on Days 1, 4, and 7. Blood was collected on Day 8 and plasma concentrations of (B) PCSK9, (C) triglycerides (TG), (D) total cholesterol (TC), (E) non-high-density-lipoprotein cholesterol (non-HDL-C), (F) high-density-lipoprotein cholesterol (HDL-C), and (G) oxidized low-density-lipoprotein cholesterol (ox-LDL) were measured (n=5). The results are presented as mean ± SE, N = 5. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ , statistically significant compared with the control group (Tukey's test). # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$ , #### $P < 0.0001$ , statistically significant compared with the atorvastatin + DS-9001a group (Tukey's test).

JPET #246652

**Table 1 Measurement of binding affinity of DS-9001a and DS-9001a without ABD to human PCSK9 and HSA.**

The binding affinities of DS-9001a and DS-9001a without ABD to biotinylated PCSK9 and human serum albumin (HSA) were measured by a surface plasmon resonance (SPR)-based assay. The association rate constants ( $k_a$ ) and dissociation rate constants ( $k_d$ ) were determined and the dissociation constants ( $K_D$ ) were calculated based on them.

Molecule	Anti-PCSK9			Anti-HSA		
	$k_a$ (1/Ms)	$k_d$ (1/s)	$K_D$ (M)	$k_a$ (1/Ms)	$k_d$ (1/s)	$K_D$ (M)
DS-9001a	7.1E+05	2.7E-04	3.8E-10	2.2E+06	4.2E-05	1.9E-11
DS-9001a without ABD	1.1E+05	2.9E-04	2.6E-10			

Figure 1




Figure 2




Figure 3





Figure 4




Figure 5

